{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:07:59Z","timestamp":1784196479260,"version":"3.55.0"},"reference-count":25,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objectives: Novel agents such as brentuximab vedotin and anti-PD-1 antibodies, together with PET-adapted intensified strategies, have improved outcomes in advanced-stage classical Hodgkin lymphoma (cHL). However, their applicability remains limited in many middle-income countries because of restricted drug availability, reimbursement barriers, and toxicity concerns. Therefore, real-world data on the effectiveness of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) remains essential. Methods: We conducted a retrospective two-center study including 95 patients with newly diagnosed cHL treated with first-line ABVD. Baseline characteristics, treatment response, progression-free survival (PFS), overall survival (OS), and mortality were compared between early-stage (I\u2013II, n = 33) and advanced-stage (III\u2013IV, n = 62) disease. Results: The median age was 38 years (range, 18\u201373), and 69.5% were male; 65% had advanced-stage. Complete response rates were high in both early-stage (97%) and advanced-stage (95.2%) patients. Median PFS (21 vs. 23 months; p = 0.994) and OS (23 vs. 25 months; p = 0.848) were similar. Five-year OS was 84.3% for early-stage and 98% for advanced-stage patients (p = 0.292), while five-year PFS was 55.3% and 29.6% (p = 0.526). Mortality rates were comparable. Conclusions: In this real-world cohort, first-line ABVD achieved high response rates and favorable long-term survival in advanced-stage cHL, supporting its continued use as a frontline treatment option, particularly in settings where access to novel therapies may be limited.<\/jats:p>","DOI":"10.3390\/jcm15145579","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:23:14Z","timestamp":1784193794000},"page":"5579","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Frontline ABVD Remains an Effective Option in Advanced-Stage Classical Hodgkin Lymphoma: Real-World Data from Turkey"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9449-8759","authenticated-orcid":false,"given":"Derya","family":"Demirtas","sequence":"first","affiliation":[{"name":"Department of Hematology, Adana City Training and Research Hospital, University of Health Sciences, 01230 Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Suyani","sequence":"additional","affiliation":[{"name":"Department of Hematology, Adana City Training and Research Hospital, University of Health Sciences, 01230 Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alper","family":"Koc","sequence":"additional","affiliation":[{"name":"Department of Hematology, Elaz\u0131g Fethi Sekin City Hospital, 23280 Elaz\u0131g, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Aygun","sequence":"additional","affiliation":[{"name":"Department of Hematology, Adana City Training and Research Hospital, University of Health Sciences, 01230 Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep Tugba","family":"Karabulut","sequence":"additional","affiliation":[{"name":"Department of Hematology, Adana City Training and Research Hospital, University of Health Sciences, 01230 Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0895-4787","authenticated-orcid":false,"given":"Nurhilal","family":"Buyukkurt","sequence":"additional","affiliation":[{"name":"Department of Hematology, Adana City Training and Research Hospital, University of Health Sciences, 01230 Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cagatay","family":"Unsal","sequence":"additional","affiliation":[{"name":"Department of Hematology, Adana City Training and Research Hospital, University of Health Sciences, 01230 Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7282-0188","authenticated-orcid":false,"given":"Didar Yanardag","family":"Acik","sequence":"additional","affiliation":[{"name":"Department of Hematology, Adana City Training and Research Hospital, University of Health Sciences, 01230 Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(20)32207-8","article-title":"Classical Hodgkin lymphoma","volume":"398","author":"Brice","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4103\/ijmr.ijmr_3459_21","article-title":"Long-term clinical outcomes of combined modality therapy for advanced-stage Hodgkin lymphoma in the PET era: A retrospective study","volume":"159","author":"Chugh","year":"2024","journal-title":"Indian J. Med. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s00262-025-04041-z","article-title":"Improved efficacy of concurrent anti-PD1 antibody plus AVD versus ABVD in patients with newly diagnosed early unfavorable and advanced stage classic Hodgkin lymphoma: A retrospective matched cohort study","volume":"74","author":"Wu","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.aogh.2016.08.001","article-title":"Challenges to Cancer Program Development in Low- and Middle-Income Countries","volume":"82","author":"Beddoe","year":"2016","journal-title":"Ann. Glob. Health"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41571-022-00700-7","article-title":"Barriers in access to oncology drugs\u2014A global crisis","volume":"20","author":"Barrios","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Bhurani, D., Nair, R., Rajappa, S., Rao, S.A., Sridharan, N., Boya, R.R., Raman, G.S., Menon, H., Seshachalam, A., and Nimmagadda, R. (2022). Real-World Outcomes of Hodgkin Lymphoma: A Multi-Centric Registry From India. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.799948"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/ajh.27470","article-title":"Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management","volume":"99","author":"Ansell","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin\u2019s Lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in Advanced-Stage Classic Hodgkin\u2019s Lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_12","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma","volume":"141","author":"Lynch","year":"2023","journal-title":"Blood"},{"key":"ref_13","unstructured":"National Comprehensive Cancer Network (2025). NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma, National Comprehensive Cancer Network. Version 1.2026."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s00228-023-03557-6","article-title":"Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: A systematic review","volume":"79","author":"Arabloo","year":"2023","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Raymakers, A.J.N., Costa, S., Cameron, D., and Regier, D.A. (2020). Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin\u2019s lymphoma: A probabilistic analysis. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07374-3"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1200\/JCO.18.00122","article-title":"Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma","volume":"36","author":"Huntington","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/13696998.2018.1542599","article-title":"Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma","volume":"22","author":"Delea","year":"2019","journal-title":"J. Med. Econ."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e70165","DOI":"10.1002\/hon.70165","article-title":"International Cost-Effectiveness Analysis of Nivolumab Versus Brentuximab Vedotin for Patients With Advanced-Stage Classic Hodgkin\u2019s Lymphoma","volume":"44","author":"Zhu","year":"2026","journal-title":"Hematol. Oncol."},{"key":"ref_19","first-page":"590836","article-title":"Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis","volume":"18","author":"Li","year":"2026","journal-title":"Clin. Outcomes Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bjhh.2017.08.004","article-title":"Hodgkin\u2019s lymphoma in developing countries: Can we go further?","volume":"39","author":"Gaiolla","year":"2017","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Massaro, F., Andreozzi, F., Vandevoorde, C., and Bron, D. (2023). Supportive Care in Older Lymphoma Patients to Reduce Toxicity and Preserve Quality of Life. Cancers, 15.","DOI":"10.3390\/cancers15225381"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/cncr.32718","article-title":"Associations between nutritional factors and chemotherapy toxicity in older adults with solid tumors","volume":"126","author":"Dotan","year":"2020","journal-title":"Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.tips.2004.02.007","article-title":"Pharmacogenetics of cytochrome P450 and its applications in drug therapy: The past, present and future","volume":"25","author":"Sundberg","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1053\/j.seminhematol.2024.06.003","article-title":"The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era","volume":"61","author":"Varma","year":"2024","journal-title":"Semin. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"22211","DOI":"10.1038\/s41598-025-07187-z","article-title":"Treatment outcomes of ABVD in classical Hodgkin lymphoma patients from Thailand without procarbazine access","volume":"15","author":"Suttantapidok","year":"2025","journal-title":"Sci. Rep."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5579\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:38:50Z","timestamp":1784194730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":25,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15145579"],"URL":"https:\/\/doi.org\/10.3390\/jcm15145579","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]}}}